These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24978361)

  • 1. Impact of active surveillance on pathology and nerve sparing status.
    Sussman R; Staff I; Tortora J; Champagne A; Meraney A; Kesler SS; Wagner JR
    Can J Urol; 2014 Jun; 21(3):7299-304. PubMed ID: 24978361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort.
    Shee K; Cowan JE; Washington SL; Shinohara K; Nguyen HG; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2024 Aug; 7(4):838-843. PubMed ID: 38057193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
    Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
    Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure.
    Palisaar RJ; Noldus J; Graefen M; Erbersdobler A; Haese A; Huland H
    Eur Urol; 2005 Feb; 47(2):176-84. PubMed ID: 15661411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity is not associated with aggressive pathologic features or biochemical recurrence after radical prostatectomy.
    Tomaszewski JJ; Chen YF; Bertolet M; Ristau BT; Woldemichael E; Nelson JB
    Urology; 2013 May; 81(5):992-6. PubMed ID: 23453649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance.
    Norman Z; Militza P; Andres F; Daniela F; Alejandro M; Catherine S; Juan F
    Int Braz J Urol; 2014; 40(2):154-9. PubMed ID: 24856482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
    Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
    Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysis.
    Korets R; Seager CM; Pitman MS; Hruby GW; Benson MC; McKiernan JM
    BJU Int; 2012 Jul; 110(2):211-6. PubMed ID: 22093486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
    Boorjian SA; Bianco FJ; Scardino PT; Eastham JA
    BJU Int; 2005 Oct; 96(6):773-6. PubMed ID: 16153197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
    Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
    BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: can nerve-sparing surgery increase the risk?
    Røder MA; Thomsen FB; Christensen IJ; Toft BG; Brasso K; Vainer B; Iversen P
    Scand J Urol; 2014 Feb; 48(1):15-20. PubMed ID: 23181451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence.
    Corcoran NM; Hong MK; Casey RG; Hurtado-Coll A; Peters J; Harewood L; Goldenberg SL; Hovens CM; Costello AJ; Gleave ME
    BJU Int; 2011 Oct; 108(8 Pt 2):E202-10. PubMed ID: 21443656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.